Louisiana Health Service and Indemnity, operating as Blue Cross and Blue Shield of Louisiana (BCBSLA), is an independent licensee of the Blue Cross and Blue Shield Association. It provides health insurance products and related services to more than 1.1 million members from offices across the Bayou state.

Hyderabad-based Natco Pharma stated that the company along with Celgene Corporation, Bristol Myers Squibb and Breckenridge Pharmaceutical Inc. has been named defendants in an antitrust lawsuit in the US by Louisiana Health Service & Indemnity Company and HMO Louisiana Inc. regarding Pomalidomide (POMALYST).

“Natco believes this matter is without merit. Breckenridge is the ANDA holder and distribution partner for the generic product in the US,” the company said in a statement.

Natco Pharma is engaged in the business of pharmaceuticals which comprises research and development, manufacturing and selling of bulk drugs and finished dosage formulations. The company has manufacturing facilities in India which caters to both domestic and international markets including regulated markets like United States of America and Europe.

The company reported 31.18% rise in consolidated net profit to Rs 420.30 crore on a 28.93% increase in sales to Rs 1,140.50 crore in Q1 FY24 over Q1 FY23.